Automated News

Facet Biotech Wooed by $722M Acquisition Offer from Abbott (BioWorld)

Automated News - Automated News

Wednesday, 10 March 2010 20:33

Three months after Biogen Idec Inc. failed to acquire Facet Biotech Corp. for $17.50 per share, Abbott is getting the job done with a $27-per-share offer.

Write comment (0 Comments)

Study - Long Term Use of Bisphosphonates Linked To Hip Fractures (InjuryBoard)

Automated News - Automated News

Wednesday, 10 March 2010 15:25

LEARN MORE InjuryBoard on Fosamax InjuryBoard on Osteoporosis National Osteoporosis Foundation WebMD on Bisphosphonate Drugs IMAGE SOURCE: © Fosamax for Osteoporosis Treatment Fosamax, one in a class of drugs known as bisphosphonates, is supposed to make bones stronger. But new research suggests staying on the drug for five or more years can increase the risk of hip fractures . Two new studies ...

Write comment (0 Comments)

Expert on multiple myeloma to speak at UK Friday (Lexington Herald-Leader)

Automated News - Automated News

Wednesday, 10 March 2010 14:58

The University of Kentucky's Markey Cancer Center and Jessamine County businessman R.J. Corman

Write comment (0 Comments)

Mayo Clinic Receives Unique Philanthropic Gift for Cancer Research (Business Wire via Yahoo! Finance)

Automated News - Automated News

Wednesday, 10 March 2010 14:55

SCOTTSDALE, Ariz.----Mayo Clinic is forming a new permanent professorship to augment cancer research that will focus on finding new treatments and preventive measures to reduce the incidence of cancer.

Write comment (0 Comments)

A blood test for breast cancer? Researchers hopeful (CTV.ca)

Automated News - Automated News

Wednesday, 10 March 2010 13:41

U.S. researchers are working on an experimental DNA test that could pave the way for a simple blood test to detect breast cancer.

Write comment (0 Comments)

Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients

Automated News - Automated News

Wednesday, 10 March 2010 13:00

Exposure to prior myeloma therapies, specifically thalidomide (Thalomid) and autologous stem cell transplants (ASCT), does not influence the superior efficacy of Velcade (bortezomib) compared to dexamethasone (Decadron) in patients with relapsed/refractory myeloma, according to an analysis published in the British Journal of

Write comment (0 Comments)

Book helps patients navigate cancer (Laguna Woods Globe)

Automated News - Automated News

Wednesday, 10 March 2010 11:36

Gordon Aldrich was diagnosed with multiple myeloma, a rare blood cancer, on May 13, 2004. He died May 13, 2006, two years to the day later. He was 43. But maybe he died too soon? Maybe his treatment was ineffective? Maybe his cancer team wasn't the...

Write comment (0 Comments)

Abbott on Acquisition Spree (Zacks.com via Yahoo! Finance)

Automated News - Automated News

Wednesday, 10 March 2010 09:37

Abbott has recently announced its intention to acquire Facet Biotech Corporation for $27 per share.

Write comment (0 Comments)

Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference (PR Newswire via Yahoo! Finance)

Automated News - Automated News

Wednesday, 10 March 2010 08:30

Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA.

Write comment (0 Comments)

ImmunoCellular Therapeutics' Dendritic Cell-Based Vaccine Demonstrates Statistically Significant Increase in Survival ... (Business Wire via Yahoo! Finance)

Automated News - Automated News

Wednesday, 10 March 2010 08:00

LOS ANGELES----ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

Write comment (0 Comments)

ImmunoGen, Inc. Announces Orphan Drug Designation Granted To IMGN901 For Treatment Of Merkel Cell Carcinoma By US FDA ... (Medical News Today)

Automated News - Automated News

Tuesday, 09 March 2010 22:14

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European ...

Write comment (0 Comments)

Facet Biotech Stock Soars on Abbott Bid (TheStreet.com)

Automated News - Automated News

Tuesday, 09 March 2010 19:00

Shares of drug maker Facet Biotech skyrocket after Abbott announced an acquisition bid valuing Facet at $27 a share.

Write comment (0 Comments)

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech (redOrbit)

Automated News - Automated News

Tuesday, 09 March 2010 18:15

ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

Write comment (0 Comments)

Abbott Enhances Pharmaceutical Pipeline with Acquisition . (Stock World)

Automated News - Automated News

Tuesday, 09 March 2010 17:08

ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

Write comment (0 Comments)

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech (FinanzNachrichten)

Automated News - Automated News

Tuesday, 09 March 2010 17:02

ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 (ots/PRNewswire) - Abbott and Facet Biotech Corporation announced today a definitive ...

Write comment (0 Comments)

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech (Presseportal)

Automated News - Automated News

Tuesday, 09 March 2010 16:57

Write comment (0 Comments)

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech (PR Newswire via Yahoo! Finance)

Automated News - Automated News

Tuesday, 09 March 2010 16:52

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Â Abbott will acquire Facet for $27 per share in cash for a net transaction value of approximately $450 million, which includes a purchase price of approximately $722 million less Facet's projected cash and marketable securities ...

Write comment (0 Comments)

ACS Stats Find Gains in War on Cancer

Automated News - Automated News

Tuesday, 09 March 2010 15:44

Cancer is not quite the killer it was 20 years ago. The American Cancer Society found that "age-standardized" cancer deaths among men declined by 21% from 1990, while the rate among women declined by 12% from 1991 to 2006.

Write comment (0 Comments)

ImmunoGen cancer drug granted orphan drug status (Mass High Tech: The Journal of New England Technology)

Automated News - Automated News

Tuesday, 09 March 2010 14:21

ImmunoGen Inc. reports the U.S. Food and Drug Administration and the EU Committee for Orphan Medicinal Products has granted orphan drug status to an ImmunoGen compound used to treat Merkel cell carcinoma (MCC).

Write comment (0 Comments)

Infectious Virus Hidden In Chromosomes During Latency Can Be Passed From Parents To Children (Medical News Today)

Automated News - Automated News

Tuesday, 09 March 2010 10:31

Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life. Now, a team led by Peter Medveczky, MD, a professor in the Department of Molecular Medicine at the University of South Florida (USF), has discovered that in some individuals, HHV-6 causes such a permanent infection by inserting or "integrating" its ...

Write comment (0 Comments)

Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer (News-Medical-Net)

Automated News - Automated News

Tuesday, 09 March 2010 08:07

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified ...

Write comment (0 Comments)

Page 1 of 19